Olivia Dean

Summary

Affiliation: Barwon Health
Country: Australia

Publications

  1. pmc N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action
    Olivia Dean
    Mental Health Research Institute, Parkville, Victoria, Australia
    J Psychiatry Neurosci 36:78-86. 2011
  2. pmc Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial
    Michael Berk
    Deakin University, School of Medicine, Barwon Health, P O Box 291, Geelong, 3220, Australia
    BMC Med 10:91. 2012
  3. doi request reprint Minocycline: therapeutic potential in psychiatry
    Olivia M Dean
    Deakin University, School of Medicine, Barwon Health, Geelong, Vic, Australia
    CNS Drugs 26:391-401. 2012
  4. doi request reprint N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: relevance to schizophrenia and bipolar disorder
    Olivia M Dean
    The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Neurosci Lett 499:149-53. 2011
  5. doi request reprint Interaction of glutathione depletion and psychotropic drug treatment in prepulse inhibition in rats and mice
    Olivia Dean
    Mental Health Research Institute, 155 Oak Street, Parkville, Victoria 3052, Australia
    Pharmacol Biochem Behav 97:293-300. 2010
  6. ncbi request reprint A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice
    O M Dean
    The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Curr Med Chem 16:2965-76. 2009
  7. doi request reprint Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice
    Olivia Dean
    Mental Health Research Institute, 155 Oak Street, Parkville, Victoria 3052, Australia
    Behav Brain Res 198:258-62. 2009
  8. doi request reprint Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats
    Kwok Ho Christopher Choy
    Mental Health Research Institute, Parkville, Victoria, Australia
    Eur J Pharmacol 649:224-8. 2010
  9. ncbi request reprint N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial
    Michael Berk
    The Mental Health Research Institute of Victoria, Victoria, Australia
    Biol Psychiatry 64:468-75. 2008
  10. ncbi request reprint Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia
    Michael Berk
    Department of Clinical and Biomedical Sciences Barwon Health, University of Melbourne, PO Box 281, Geelong 3220, Victoria, Australia
    J Clin Psychiatry 72:909-13. 2011

Detail Information

Publications17

  1. pmc N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action
    Olivia Dean
    Mental Health Research Institute, Parkville, Victoria, Australia
    J Psychiatry Neurosci 36:78-86. 2011
    ..The therapeutic potential of this acetylated amino acid is beginning to emerge in the field of psychiatric research...
  2. pmc Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial
    Michael Berk
    Deakin University, School of Medicine, Barwon Health, P O Box 291, Geelong, 3220, Australia
    BMC Med 10:91. 2012
    ..The current study aimed to investigate the maintenance effects of NAC following eight weeks of open-label treatment for bipolar disorder...
  3. doi request reprint Minocycline: therapeutic potential in psychiatry
    Olivia M Dean
    Deakin University, School of Medicine, Barwon Health, Geelong, Vic, Australia
    CNS Drugs 26:391-401. 2012
    ..Given the limited data from rigorous clinical trials, further research is required. However, taken together, the current evidence suggests minocycline may be a promising novel therapy in psychiatry...
  4. doi request reprint N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: relevance to schizophrenia and bipolar disorder
    Olivia M Dean
    The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Neurosci Lett 499:149-53. 2011
    ..While NAC was shown to be beneficial in this model, the lack of additional glutathione depletion by amphetamine in combination with CHX does not support a summative interaction between oxidative stress and altered dopamine transmission...
  5. doi request reprint Interaction of glutathione depletion and psychotropic drug treatment in prepulse inhibition in rats and mice
    Olivia Dean
    Mental Health Research Institute, 155 Oak Street, Parkville, Victoria 3052, Australia
    Pharmacol Biochem Behav 97:293-300. 2010
    ..The significance of these results for schizophrenia is discussed...
  6. ncbi request reprint A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice
    O M Dean
    The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Curr Med Chem 16:2965-76. 2009
    ....
  7. doi request reprint Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice
    Olivia Dean
    Mental Health Research Institute, 155 Oak Street, Parkville, Victoria 3052, Australia
    Behav Brain Res 198:258-62. 2009
    ..In conclusion, GSH depletion induces cognitive impairment, which may be relevant to the role of GSH in psychiatric illnesses...
  8. doi request reprint Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats
    Kwok Ho Christopher Choy
    Mental Health Research Institute, Parkville, Victoria, Australia
    Eur J Pharmacol 649:224-8. 2010
    ..These effects appear to be dose-dependent and region-specific. These results may be relevant to the understanding and management of the cognitive symptoms of schizophrenia and bipolar disorder...
  9. ncbi request reprint N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial
    Michael Berk
    The Mental Health Research Institute of Victoria, Victoria, Australia
    Biol Psychiatry 64:468-75. 2008
    ..We hypothesized that treatment with N-acetyl cysteine (NAC), a safe, orally bioavailable precursor of glutathione, may improve the depressive component of bipolar disorder...
  10. ncbi request reprint Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia
    Michael Berk
    Department of Clinical and Biomedical Sciences Barwon Health, University of Melbourne, PO Box 281, Geelong 3220, Victoria, Australia
    J Clin Psychiatry 72:909-13. 2011
    ..To our knowledge, this mixed methodology has not previously been applied to blinded psychopharmacologic trials...
  11. doi request reprint The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial
    Michael Berk
    Department of Psychiatry, The University of Melbourne, Parkville, Australia
    J Affect Disord 135:389-94. 2011
    ..Given the failure of almost all modern trials of antidepressants in bipolar disorder to demonstrate efficacy, and the limited efficacy of mood stabilisers in the depressive phase of the disorder, this is a major unmet need...
  12. doi request reprint Who's left? Symptoms of schizophrenia that predict clinical trial dropout
    Jason Thompson
    Department of Clinical and Biomedical Sciences Barwon Health, University of Melbourne, Melbourne, Victoria, Australia
    Hum Psychopharmacol 26:609-13. 2011
    ..These findings reflect important considerations for the future design of clinical trials involving people with schizophrenia and may also provide clues into treatment compliance issues more generally...
  13. doi request reprint Oxidative stress in psychiatric disorders: evidence base and therapeutic implications
    Felicity Ng
    Department of Clinical and Biomedical Sciences, Barwon Health, University of Melbourne, Geelong, Vic, Australia
    Int J Neuropsychopharmacol 11:851-76. 2008
    ..These data not only suggest that oxidative mechanisms may form unifying common pathogenic pathways in psychiatric disorders, but also introduce new targets for the development of therapeutic interventions...
  14. doi request reprint Glutathione: a novel treatment target in psychiatry
    Michael Berk
    Department of Clinical and Biomedical Sciences, Barwon Health, University of Melbourne, Geelong, Victoria, Australia
    Trends Pharmacol Sci 29:346-51. 2008
    ..This article outlines the multidimensional evidence that currently exists for oxidative stress mechanisms in psychiatric disorders and specifically discusses glutathione as a promising novel therapeutic target...
  15. pmc Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness
    Michael Berk
    School of Medicine, Deakin University, 75 Pigdon s Road, Waurn Ponds, Geelong, Victoria 3216, Australia
    BMC Med 11:74. 2013
    ....
  16. ncbi request reprint N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility
    Seetal Dodd
    University of Melbourne, Department of Clinical and Biomedical Sciences, Barwon Health, PO Box 281, Geelong 3220, Victoria, Australia
    Expert Opin Biol Ther 8:1955-62. 2008
    ..Treatment with N-acetylcysteine (NAC) has been shown to increase levels of glutathione. NAC has been proposed as a treatment for several illnesses...
  17. doi request reprint N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial
    Michael Berk
    The Mental Health Research Institute of Victoria, Parkville, Australia
    Biol Psychiatry 64:361-8. 2008
    ..This study was conducted to evaluate the safety and effectiveness of oral NAC (1 g orally twice daily [b.i.d.]) as an add-on to maintenance medication for the treatment of chronic schizophrenia over a 24-week period...